- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04275843
The Effects of Western Diet Patterns on Plasma Inflammatory and Cardio Metabolic Health Signatures in Middle-aged Adults
The Western diet pattern or standard American diet is a modern dietary pattern that is characterized by high intakes of meat, pre-packaged foods, fried foods, high-fat dairy products, eggs, refined grains etc. When considering the role of saturated fat, it may be prudent to advise limiting all foods that contain saturated fats, including unprocessed/minimally processed meat, eggs, whole dairy in addition to processed, pre-packaged foods; however, this reductionist approach fails to take into account the food matrix and overall diet in which these nutrients are consumed.
Epidemiological evidence suggests that increased modern, pre-packaged food consumption is a major risk factor for metabolic disease by promoting inflammation. Based on these data, the investigators hypothesize that the pro-atherogenic effect of the Western diet is caused by the pro-inflammatory effects of consuming large amounts of modern ultra-processed foods, and that consumption of a similar amount of fat from minimally processed beef, poultry, dairy, eggs, as part of an unprocessed diet will positively impact inflammatory markers and lipoprotein profiles of study participants when compared to a diet rich in modern ultra-processed foods.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27701
- Duke University School of Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age ≥35 and ≤60 years;
- BMI ≥25 and ≤35 kg/m2;
- Weight stable in last 3 months (Loss or gain <4%);
- Consistent physical activity levels;
- Hemoglobin A1C (HbA1C) ≤6.4%;
- Fasting insulin; <15 µU/mL;
- Fasting plasma glucose concentration <126 mg/dl;
- Willingness to eat the food provided in this study;
- Subjects must be able to speak and understand English to participate in this study
- Own a smartphone or other mobile device capable of downloading the Garmin Connect app.
Exclusion Criteria:
- Diagnoses of active malignancy, congestive heart failure, diabetes mellitus, chronic obstructive pulmonary disease, thyroid disease or other metabolic disorders that influence metabolism;
- Evidence of impaired kidney function (Estimated glomerular filtration rate [eGFR] <44 mL/min;
- Regular use of medication that interferes with the measurement of study outcomes as determined by the study team (e.g., NSAIDs, corticosteroids);
- Consuming >14 drinks per week of >4 drinks per night twice/week for male; >7 drinks per week or >3 drinks per night twice/week for female;
- Use of cigarettes (or other tobacco products) or use of any other (recreational) drug in last 3 months;
- Engaged in high-level competitive exercise (e.g., marathons, triathlons, cycling, weight-lifting competitions etc.)
- Self-reported sleep duration <5 hours per night;
- Any inflammatory diseases (e.g. asthma, autoimmune diseases, coeliac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, arthritis);
- Use of antibiotics in last 30 days;
- Pregnant or lactating women;
- Eating disorders (e.g., anorexia nervosa, bulimia nervosa, binge eating disorders etc.)
- Psychological disorders (e.g., clinical depression, bipolar disorders etc.);
- Strict dietary patterns (e.g., vegan, carnivore, kosher, low-carb etc.);
- History of stomach or bowel resection (other than appendectomy), gastric bypass or other bariatric weight loss procedure effecting absorption;
- Persons who are not able to grant voluntary informed consent;
- Persons who are unable or unwilling to follow the study protocol or who, for any reason, the research team considers not an appropriate candidate for this study, including non-compliance with screening appointments or study visits.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Traditional Diet
Unprocessed/minimally processed whole foods.
|
Consuming an traditional whole foods based diet for 4 weeks.
|
Aktiver Komparator: Modern Diet
Multi-ingredient, ultra-processed formulations of the traditional diet.
|
Consuming an processed formulation of the traditional diet for 4 weeks.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in plasma interleukin-6 levels
Zeitfenster: Baseline, up to 4 weeks.
|
Plasma interleukin-6 levels will be measured before and after each diet
|
Baseline, up to 4 weeks.
|
Change in plasma c-reactive protein levels
Zeitfenster: Baseline, up to 4 weeks.
|
Plasma c-reactive protein levels levels will be measured before and after each diet
|
Baseline, up to 4 weeks.
|
Change in plasma acylcarnitine profiles
Zeitfenster: Baseline, up to 4 weeks.
|
Plasma acylcarnitines profiles levels will be measured before and after each diet
|
Baseline, up to 4 weeks.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change in gut microbiota communities
Zeitfenster: Baseline, up to 4 weeks.
|
Bifidobacterium, Faecalibacterium prausnitzii, Anerostipes, Roseburia
|
Baseline, up to 4 weeks.
|
Energy expenditure
Zeitfenster: up to 4 weeks.
|
Measured by the doubly labeled water method during the last week of each diet
|
up to 4 weeks.
|
Change in Neuroinflammation
Zeitfenster: Baseline, up to 4 weeks.
|
Neurofilament light (NfL), glial fibrillary acidic protein (GFAP), Aß42 and p-tau will be measured before and after each diet
|
Baseline, up to 4 weeks.
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Studienleiter: Stephan van Vliet, PhD, Duke University
- Hauptermittler: Kim Huffman, MD, PhD, Duke University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- Pro00103827
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Traditional Diet
-
Omni MedUnbekanntTelemedizin | GemeindegesundheitsdiensteVereinigte Staaten, Uganda
-
Mondelēz International, Inc.KGK Science Inc.Abgeschlossen
-
Mondelēz International, Inc.KGK Science Inc.Abgeschlossen
-
Shirley Ryan AbilityLabOtto Bock Healthcare Products GmbHRekrutierung
-
Università degli Studi di BresciaAbgeschlossen
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekrutierungFettleibigkeit | Diabetes mellitus, Typ 2 | Insulinresistenz | Prädiabetes | Ernährungsumstellung | Nichtalkoholische Stratohepatitis | Alkoholfreie FettleberVereinigte Staaten
-
University Hospital TuebingenRekrutierung
-
Jens Rikardt AndersenNutricia, Inc.; Nordsjaellands HospitalUnbekanntNierenerkrankungen | Hypertonie | Diabetes mellitus, Typ 2 | Diabetes Mellitus | Diabetes-Komplikationen | Diabetes mellitus, Typ 1 | Glomerulonephritis | Nierenerkrankung, chronisch | NiereninsuffizienzDänemark
-
Universidad de SonoraNoch keine RekrutierungFettleibigkeit | ÜbergewichtMexiko
-
Universiti Putra MalaysiaRekrutierungChronische Nierenerkrankungen | Chronische Nierenerkrankung Stufe 5 | Chronische Nierenerkrankung stage4 | Chronische Nierenerkrankung stage3 | Chronische Nierenerkrankung, die eine chronische Dialyse erfordertMalaysia